FDA and Precision Medicine 2017- An Interim Report from Washington


Change and uncertainty accompany any political transition, and as the new administration was taking shape back in the early part of the year, FDA-regulated stakeholders had many
questions and concerns about what regulatory changes might be in store for them in the next few years. While drug pricing rhetoric and the brief floating of a couple unconventional
names as potential FDA Commissioners caught industry’s attention early on, with the confirmation of Dr. Gottlieb as FDA Commissioner and political attention focused on Congressional efforts to repeal the Affordable Care Act, the FDA has been a relatively quiet haven from the usual Washington politics thus far.

View PDF